期刊
MEDICINAL RESEARCH REVIEWS
卷 35, 期 5, 页码 937-967出版社
WILEY
DOI: 10.1002/med.21348
关键词
fungal metabolites; clinical trials; drug resistance; anguidine; aphidicolin; rhizoxin; fumagillin; illudin S; phenylahistin; wortmannin
资金
- Welch Foundation [AI-0045]
- National Intstitutes of Health [1R15-CA186046-01A1]
- National Science Foundation [0946998]
- National Research Foundation (South Africa)
- Stellenbosch University
- Direct For Mathematical & Physical Scien
- Division Of Chemistry [0946998] Funding Source: National Science Foundation
Although fungi produce highly structurally diverse metabolites, many of which have served as excellent sources of pharmaceuticals, no fungi-derived agent has been approved as a cancer drug so far. This is despite a tremendous amount of research being aimed at the identification of fungal metabolites with promising anticancer activities. This review discusses the results of clinical testing of fungal metabolites and their synthetic derivatives, with the goal to evaluate how far we are from an approved cancer drug of fungal origin. Also, because in vivo studies in animal models are predictive of the efficacy and toxicity of a given compound in a clinical situation, literature describing animal cancer testing of compounds of fungal origin is reviewed as well. Agents showing the potential to advance to clinical trials are also identified. Finally, the technological challenges involved in the exploitation of fungal biodiversity and procurement of sufficient quantities of clinical candidates are discussed, and potential solutions that could be pursued by researchers are highlighted. (C) 2015 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据